HUTCHMED (NASDAQ:HCM) Sees Unusually-High Trading Volume

HUTCHMED (China) Limited (NASDAQ:HCM) shares saw an uptick in trading volume on Wednesday . 93,397 shares traded hands during mid-day trading, a decline of 24% from the previous session’s volume of 123,022 shares.The stock last traded at $20.47 and had previously closed at $20.00.

Wall Street Analysts Forecast Growth

HCM has been the topic of a number of recent analyst reports. StockNews.com cut HUTCHMED from a “buy” rating to a “hold” rating in a report on Thursday, July 18th. The Goldman Sachs Group lifted their target price on HUTCHMED from $17.00 to $19.00 and gave the stock a “neutral” rating in a report on Thursday, August 1st.

HUTCHMED Stock Performance

The company has a quick ratio of 2.68, a current ratio of 2.81 and a debt-to-equity ratio of 0.07. The stock’s 50 day simple moving average is $18.06 and its two-hundred day simple moving average is $18.17.

Institutional Trading of HUTCHMED

Several hedge funds and other institutional investors have recently modified their holdings of the company. Rhumbline Advisers raised its holdings in shares of HUTCHMED by 8.1% in the second quarter. Rhumbline Advisers now owns 7,553 shares of the company’s stock valued at $129,000 after purchasing an additional 564 shares during the last quarter. Vanguard Personalized Indexing Management LLC grew its position in HUTCHMED by 9.7% in the second quarter. Vanguard Personalized Indexing Management LLC now owns 13,216 shares of the company’s stock valued at $226,000 after purchasing an additional 1,168 shares in the last quarter. Hennion & Walsh Asset Management Inc. increased its stake in HUTCHMED by 2.5% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 57,010 shares of the company’s stock valued at $958,000 after buying an additional 1,388 shares during the last quarter. China Universal Asset Management Co. Ltd. lifted its position in HUTCHMED by 65.1% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 5,933 shares of the company’s stock worth $100,000 after buying an additional 2,340 shares in the last quarter. Finally, Russell Investments Group Ltd. boosted its stake in shares of HUTCHMED by 70.5% during the 1st quarter. Russell Investments Group Ltd. now owns 18,179 shares of the company’s stock worth $304,000 after buying an additional 7,515 shares during the last quarter. Institutional investors and hedge funds own 8.82% of the company’s stock.

HUTCHMED Company Profile

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors.